deruxtecan

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

VcMMAE-Deruxtecan is a toxic molecular conjugate (Drug-Linker Conjugates for ADC) composed of a linker and cytotoxic agents MMAE (microtubule inhibitor) and Exatecan (DNA topoisomerase I inhibitor). This compound is employed in the synthesis of ADCs.

Deruxtecan-Eribulin is a Drug-Linker Conjugate for ADC comprised of a linker and two cytotoxic molecules: Exatecan (a DNA topoisomerase I inhibitor) and Eribulin (a microtubule inhibitor). This compound is utilized in the synthesis of ADCs.

Raludotatug deruxtecan (DS-6000) is an ADC compound targeting CDH6 with anti-cancer activity, used in the study of ovarian cancer.

Deruxtecan Analog 2 (example 9 P3), a Deruxtecan derivative, serves as an agent-linker conjugate integrating Camptothecin (CPT), a Topo I inhibitor active against colorectal, breast, lung, and ovarian cancers, with a distinct linker. This analog is employed in synthesizing anti-FGFR2 ADC [1].

Deruxtecan (1R) is a drug-linker conjugate for antibody-drug conjugates (ADC) [1].

Deruxtecan analog 2 (monoTFA), a homolog of Deruxtecan, consists of the antibody-drug conjugate (ADC) toxin derivative DX-8951 (Dxd) connected through an ADC linker [1].

Gly-Mal-GGFG-Deruxtecan 2-hydroxy propionamide is a conjugate of a camptothecin-derived drug and a linker utilized for Antibody-Drug Conjugates (ADC) [1].

Ifinatamab deruxtecan (DS-7300a) is an active chemical compound utilized in various biochemical research applications.

Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.

Human IgG1 kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.

Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.

Human IgG1 (LALAPG) kappa-Deruxtecan, ADC Control is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with Fc LALAPG modification. It can be used as a control in ADC.

Human IgG1 kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate functioning as a HER2-targeted topoisomerase I inhibitor, with targeting capability and antitumor activity, employed in research on HER2-positive breast cancer and gastric cancer.

Datopotamab deruxtecan (DS-1062) is an antibody-drug conjugate (ADC) that targets tropomyosin 2 (TROP2) on the surface of trophoblast cells. Datopotamab deruxtecan exhibits antitumor activity by specifically binding to TROP2 and internalizing, releasing DXd to inhibit topoisomerase I (IC₅₀ = 0.31 μM), thereby inducing DNA damage and apoptosis. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide TFA is an ADC drug-linker conjugate containing the ADC linker Gly-Mal-GGFG and the ADC cytotoxin Deruxtecan 2-hydroxypropanamide. Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide TFA is applicable to ADC platform development, linker stability evaluation, and targeted payload delivery investigations in translational oncology and chemical biology research.

Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan. It serves as a linker-toxin structural unit in an antibody-drug conjugate (ADC) for attaching an antibody Cys residue to a cytotoxic drug. Cys-MC-GGFG-Dxd is applicable in cancer research.

Fmoc-Val-Phe-Boc serves as both a PROTAC linker and a maleimide-GGFG peptide linker. This compound is utilized in the synthesis of Deruxtecan.

Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. It can be utilized for the synthesis of Deruxtecan.

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC linker used in synthesizing drug-linker conjugates for ADCs, particularly for the creation of Deruxtecan, a potent drug-linker conjugate [1].

Ifinatamab is a humanised monoclonal immunoglobulin that targets and inhibits the B7-H3 protein. Ifinatamab can be used to synthesise the ADC drug Ifinatamab deruxtecan for the treatment of small cell lung cancer (SCLC).

Raludotatug is a humanized immunoglobulin G1-kappa (IgG1κ) monoclonal antibody that exhibits antineoplastic properties through its specific targeting of cadherin-6 (CDH6), and when conjugated to a cytotoxic payload to form the antibody-drug conjugate Raludotatug deruxtecan.Raludotatug has demonstrated promising research potential in heavily pretreated, platinum-sensitive ovarian cancer.